Abstract Background Dual antiplatelet therapy (DAPT) is key for preventing ischaemic events post‐percutaneous coronary intervention (PCI). Various DAPT modifications like the shortened duration or P2Y12 inhibitor (P2Y12i) de‐escalation are implemented to reduce bleeding risk. However, these strategies lack direct comparative studies. This study aimed to assess the efficacy and safety of such DAPT strategies, including de‐escalated and short DAPT, in patients undergoing PCI. Methods We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases for relevant randomized controlled trials (RCTs). We performed a network meta‐analysis (NMA) to estimate risk ratios (RRs) and 95% confidence intervals (C...
Aim: The aim of this meta-analysis was to evaluate the safety of 1-month dual antiplatelet therapy (...
Abstract It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) follo...
AIM: Optimal dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervent...
Aims: Dual antiplatelet therapy (DAPT) reduces the incidence of thrombotic complications at the cost...
Introduction. This network meta-analysis aimed to evaluate the efficacy and safety of different dual...
Background: Optimal duration of dual antiplatelet therapy (DAPT) in patients undergoing complex perc...
AIMS After percutaneous coronary intervention (PCI) with second-generation drug-eluting stent (DES)...
Background The efficacy and safety of an abbreviated duration of dual antiplatelet therapy (DAPT...
Background The efficacy and safety of an abbreviated duration of dual antiplatelet therapy (DAPT...
Background The efficacy and safety of an abbreviated duration of dual antiplatelet therapy (DAPT...
The optimal duration of dual antiplatelet therapy (DAPT) in the era of second-generation drug-elutin...
Background: It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic protection whi...
The optimal duration of dual antiplatelet therapy (DAPT) in the era of second-generation drug-elutin...
Background: It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic protection whi...
P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coro...
Aim: The aim of this meta-analysis was to evaluate the safety of 1-month dual antiplatelet therapy (...
Abstract It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) follo...
AIM: Optimal dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervent...
Aims: Dual antiplatelet therapy (DAPT) reduces the incidence of thrombotic complications at the cost...
Introduction. This network meta-analysis aimed to evaluate the efficacy and safety of different dual...
Background: Optimal duration of dual antiplatelet therapy (DAPT) in patients undergoing complex perc...
AIMS After percutaneous coronary intervention (PCI) with second-generation drug-eluting stent (DES)...
Background The efficacy and safety of an abbreviated duration of dual antiplatelet therapy (DAPT...
Background The efficacy and safety of an abbreviated duration of dual antiplatelet therapy (DAPT...
Background The efficacy and safety of an abbreviated duration of dual antiplatelet therapy (DAPT...
The optimal duration of dual antiplatelet therapy (DAPT) in the era of second-generation drug-elutin...
Background: It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic protection whi...
The optimal duration of dual antiplatelet therapy (DAPT) in the era of second-generation drug-elutin...
Background: It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic protection whi...
P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coro...
Aim: The aim of this meta-analysis was to evaluate the safety of 1-month dual antiplatelet therapy (...
Abstract It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) follo...
AIM: Optimal dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervent...